Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Solid Tumor × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Glioblastoma 16 Brain Neoplasms 7 Lymphoma 6 Central Nervous System Neoplasms 5 Glioma 4 Recurrence 3 Astrocytoma 3 Neoplasms 2 Medulloblastoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, AIDS-Related 2 Lung Neoplasms 2 Uveal Melanoma 1 Spinal Cord Neoplasms 1 Solid Tumor 1 Sarcoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Oligodendroglioma 1 Neoplasm Metastasis 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Leukemia-Lymphoma, Adult T-Cell 1 Kidney Neoplasms 1 Intraocular Lymphoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Gliosarcoma 1

Interventions

apatinib 3 vistusertib 2 olaparib 2 camrelizumab 2 atezolizumab 2 Ipilimumab 2 Everolimus 2 trametinib 1 tilsotolimod 1 tazemetostat 1 tazarotene 1 spartalizumab 1 sargramostim 1 sacituzumab govitecan 1 rucaparib 1 roniciclib 1 romiplostim 1 pyrotinib 1 phosphorylethanolamine 1 pemigatinib 1 pembrolizumab 1 pazopanib 1 palbociclib 1 niraparib 1 magrolimab 1 lenvatinib 1 irinotecan sucrosofate 1 famitinib 1 dalpiciclib 1 dabrafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05898451 2023-06-12

R-2

Refnot-Pharm Ltd

Phase 2 Completed

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡